Clinical Trials Browser

Phase 2/3 × Breast × 1 year × Clear all

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT05766891 2026-03-16

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Phase 2/3 Recruiting

Breast Neoplasms

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07413939 2026-03-10

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT06062810 2026-03-09

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03077841 2026-03-05

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2/3 Suspended

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04715958 2026-02-17

Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer

Phase 2/3 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT06009627 2026-02-10

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Phase 2/3 Completed

Breast Neoplasms

NCT07373782 2026-01-28

Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer

Phase 2/3 Recruiting

Microcephaly, Primary Autosomal Recessive, 6, Breast Neoplasms

NCT07366840 2026-01-26

BRIGHT

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT05860465 2026-01-14

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

Phase 2/3 Recruiting

BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

NCT07294508 2025-12-29

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Phase 2/3 Recruiting

HER2-positive Breast Cancer

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT05744687 2025-08-17

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT06958627 2025-05-06

any

Phase 2/3 Recruiting

HER2 Positive Breast Cancer

NCT05288777 2025-04-18

Breast53

Phase 2/3 Recruiting

Breast Neoplasms

NCT05555706 2025-04-15

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 2/3 Completed

Triple Negative Breast Neoplasms

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

Breast Neoplasms

NCT06910072 2025-04-04

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase 2/3 Not yet recruiting

Triple Negative Breast Neoplasms